BiotechTube

MK0686

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuralgia, Postherpetic

Conditions

Neuralgia, Postherpetic

Trial Timeline

Dec 1, 2005 → Aug 1, 2006

NCT ID
NCT00282763

About MK0686

MK0686 is a phase 2 stage product being developed by Merck for Neuralgia, Postherpetic. The current trial status is terminated. This product is registered under clinical trial identifier NCT00282763. Target conditions include Neuralgia, Postherpetic.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT00282763Phase 2Terminated
NCT00296569Phase 2Completed
NCT00533403Phase 2Completed

Competing Products

20 competing products in Neuralgia, Postherpetic

See all competitors
ProductCompanyStageHype Score
Placebo + DS-5565Daiichi SankyoPre-clinical
23
QUTENZAAstellas PharmaApproved
85
ASP8477 + PlaceboAstellas PharmaPhase 2
52
E2007 (perampanel) + PlaceboEisaiPhase 2
52
E2007EisaiPhase 2/3
65
KHK6188 + PlaceboKyowa KirinPhase 2
52
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
GalcanezumabEli LillyApproved
85
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3
77
ABT-894 + ABT-894 + ABT-894 + placebo + DuloxetineAbbViePhase 2
52
MK-8291 + PlaceboMerckPhase 1
33
Etoricoxib + PlaceboMerckApproved
85
Cetuximab + PlaceboMerckPhase 2
52
ADL5747 + Placebo + PregabalinMerckPhase 2
52
MK0759MerckPhase 2
52
Comparator: pregabalin + Comparator: Placebo (unspecified)MerckPhase 1
33
EMA401 + PlaceboNovartisPhase 2
52
pregabalinPfizerApproved
84
Lyrica (pregabalin) + PlaceboPfizerApproved
84
2-weeks placebo then gabapentin + 1-week placebo then gabapentinPfizerPre-clinical
22

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85